NetworkNewsBreaks – Endonovo Therapeutics Inc. (
Post# of 416
Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, this morning announced the appointment of Steven Levin, M.D., to its scientific advisory board. Per the update, Dr. Levin will assist Endonovo to facilitate the SofPulse(R) introduction to healthcare facilities and further develop the Electroceutical(TM) devices pipeline. “Dr. Levin's vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” ENDV CEO Alan Collier said in the news release. “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer